Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listPF-06447475

PF-06447475

Synonym(s):3-[4-(4-Morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-benzonitrile

PF-06447475 Structural

What is PF-06447475?

The Uses of PF-06447475

PF 06447475 is a highly potent LRRK2 kinase inhibitor. Highly selective, and mobile, it is used in the treatment of Parkinson’s disease which has been linked to Leucine rich repeat kinase 2 (LRRK2) enzymes.

Enzyme inhibitor

This potent, brain penetrant and selective LRRK2 inhibitor (FW = 305.44 g/mol; CAS 1527473-33-1), also named 3-[4-(4-morpholinyl)-7Hpyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile, targets Leucine-Rich Repeat Kinase 2, IC50 = 3 nM, (encoded by the PARK8 gene), which phosphorylates Akt1 (Ser-473), suggesting that Akt1 is a convincing candidate for the physiological substrate of LRRK2. Diseaseassociated mutations forms of LRRK2 (including Arg-1441-Cys, Gly-2019- Ser, and Ile-2020-Thr) exhibit reduced interaction with, and phosphorylation of, Akt1, a finding that suggests a possible mechanism for the neurodegeneration caused by LRRK2 mutations. Therapeutic approaches to slow or block the progression of Parkinson disease (PD) do not exist. Given that genetic and biochemical studies implicate α-synuclein and leucine-rich repeat kinase 2 (LRRK2) in late-onset PD. In wild-type rats as well as transgenic [Gly-2019-Ser]-LRRK2 rats that were injected intracranially with adeno-associated viral vectors expressing human α- synuclein in the substantia nigra, those expressing [Gly-2019-Ser]-LRRK2 show exacerbated dopaminergic neurodegeneration and inflammation in response to the overexpression of α-synuclein. Both neurodegeneration and neuroinflammation associated with [Gly-2019-Ser]-LRRK2 expression were mitigated by PF-06447475, which provided neuroprotection in wildtype rats. There are no adverse pathological indications in the lung, kidney, or liver of rats treated with PF-06447475. Pharmacological inhibition of LRRK2 is well tolerated for a 4-week period of time in rats and can counteract dopaminergic neurodegeneration caused by acute α-synuclein overexpression

Properties of PF-06447475

Melting point: >223°C (dec.)
Density  1.40±0.1 g/cm3(Predicted)
storage temp.  room temp
solubility  DMSO: soluble10mg/mL, clear
form  powder
pka 12.96±0.50(Predicted)
color  white to beige

Safety information for PF-06447475

Signal word Danger
Pictogram(s)
ghs
Skull and Crossbones
Acute Toxicity
GHS06
GHS Hazard Statements H301:Acute toxicity,oral
Precautionary Statement Codes P301+P310:IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

Computed Descriptors for PF-06447475

Related products of tetrahydrofuran

You may like

  • Pf-06447475 95% CAS 1527473-33-1
    Pf-06447475 95% CAS 1527473-33-1
    1527473-33-1
    View Details
  • Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 99%
    Dimethyl [2-oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonate 99%
    54094-19-8
    View Details
  • 85-81-4 99%
    85-81-4 99%
    85-81-4
    View Details
  • 208111-98-2 (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten- 1-yl]-2H-cyclopenta[b]furan-2-one 99%
    208111-98-2 (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-4-[3-(trifluoromethyl)phenoxy]-1-buten- 1-yl]-2H-cyclopenta[b]furan-2-one 99%
    208111-98-2
    View Details
  • 2033-24-1 99%
    2033-24-1 99%
    2033-24-1
    View Details
  • Meldrums acid 2033-24-1 99%
    Meldrums acid 2033-24-1 99%
    2033-24-1
    View Details
  • Cyaclopentane carboxylic acid 99%
    Cyaclopentane carboxylic acid 99%
    3400-45-1
    View Details
  • 2-Aminopyridine 504-29-0 99%
    2-Aminopyridine 504-29-0 99%
    504-29-0
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.